Reports

Ideas That Generate Results

Global Immune Checkpoint Inhibitors Market Outlook 2022

Global Immune Checkpoint Inhibitors Market Outlook 2022

Format :  Adobe Reader (PDF) Upto 24 hour delivery
Publish Date : Mar, 2020| No. of Pages : 130

Share |
 
Please make your selection :
Electronic Access - Single User License
US$ 1800.00
CD-ROM Mail Delivery
US$ 2000.00
Hard Copy Mail Delivery
US$ 2000.00
Electronic Access - Multi-User License
US$ 2500.00
1. Analyst View
 
2. Research Methodology
 
3. Immune Checkpoint Inhibitors: Overview
 
4. Market Dynamics
    4.1 Drivers
          4.1.1 Increasing Cancer Incidences
          4.1.2 Immune Checkpoint Inhibitors Sales Driving the Market Growth
          4.1.3 Growing Geriatric Population
          4.1.4 High Healthcare Spending in Developed Economies
          4.1.5 Strong Pipeline
          4.1.6 Increasing Efficacy in a Wide Variety of Indications
          4.1.7 Burgeoning Approval and Uptake of Immuno-Oncology Products
    4.2 Challenges
          4.2.1 Increasing Number of Side-Effects Post Immunotherapy Treatments
          4.2.2 Sky-High Development Costs of Cancer Immunotherapies
          4.2.3 High Cost of Treatment
          4.2.4 Lack of Awareness 
    4.3 Opportunities
          4.3.1 Opdivo and Keytruda Presents Significant Growth Opportunity 
          4.3.2 Combination Therapies Could Lead to Substantial Increases in Survival
          4.3.3 Small Companies Offering Huge Opportunites for Next Generation Immunotherapies
 
5. Global Immune Checkpoint Inhibitors Market Outlook 2022
 
6. Global Immune Checkpoint Inhibitors Sales, by Product Class
    6.1 CTLA-4 Inhibitors (Cytotoxic T-Lymphocyte-Associated Protein-4)
           6.1.1 Yervoy (Ipilimumab)
    6.2 PD-1 and PD-L1 Inhibitors(Programmed Death 1 and Programmed Death Ligand
          6.2.1 Tecentriq (Atezolizumab)
          6.2.2 Bavencio (Avelumab)
          6.2.3 Imfinzi (Durvalumab)
          6.2.4 Opdivo (Nivolumab)
          6.2.5 Keytruda (Pembrolizumab)
 
7. Application of Immune Checkpoint Inhibitors in Major Indications
    7.1 Head & Neck Cancer
    7.2 Lung Cancer
    7.3 Melanoma
    7.4 Lymphoma
    7.5 Leukemia
    7.6 Others
 
8. Trends & Developments
    8.1 Lucrative Investment Trend
    8.2 Emergence of Targeted and Combination Therapies
    8.3 NSCLC & Melanoma Showing Greatest Contributions to the IO Market
    8.4 Bristol-Myers Squibb and Merck & Co: Top Immuno-Oncology Dealmakers
 
9. Strategic Collaborations & Alliances in the Immune Checkpoint Inhibitors Market
 
10. Pipeline Analysis of Immune Checkpoint Inhibitors
 
11. Key Players Analysis
      11.1 Genentech, Inc. (A Member of the Roche Group)
      11.2 CureTech Ltd.
      11.3 NewLink Genetics Corporation 
      11.4 Novartis AG
      11.5 Bristol-Myers Squibb
      11.6 Merck & Co., Inc.
      11.7 AstraZeneca Plc
      11.8 Pfizer Inc
      11.9 Ono Pharmaceutical Co., Ltd.
      11.10 EMD Serono, Inc.
Not able to find data you are looking for? Ask our Research Analyst.

media citation

get in touch

Please fill-in the information below.